Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Dow
Johnson and Johnson
Mallinckrodt
Express Scripts

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

Alvogen Company Profile

See Plans and Pricing

« Back to Dashboard

Summary for Alvogen

Drugs and US Patents for Alvogen

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alvogen RIVASTIGMINE rivastigmine FILM, EXTENDED RELEASE;TRANSDERMAL 204403-003 Aug 31, 2015 AB RX No No   See Pricing   See Pricing
Alvogen Inc PRIMAQUINE PHOSPHATE primaquine phosphate TABLET;ORAL 203924-001 Feb 3, 2014 AB RX No No   See Pricing   See Pricing
Alvogen FELBAMATE felbamate TABLET;ORAL 204595-001 Jan 11, 2016 AB RX No No   See Pricing   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Alvogen

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alvogen ZESTORETIC hydrochlorothiazide; lisinopril TABLET;ORAL 019888-003 Nov 18, 1993 4,374,829*PED   See Pricing
Alvogen ADALAT CC nifedipine TABLET, EXTENDED RELEASE;ORAL 020198-001 Apr 21, 1993 4,892,741   See Pricing
Alvogen ZESTORETIC hydrochlorothiazide; lisinopril TABLET;ORAL 019888-001 Sep 20, 1990 4,472,380   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ALVOGEN drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 450 mg ➤ Subscribe 2013-02-28

Supplementary Protection Certificates for Alvogen Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2822954 1890030-8 Sweden   See Pricing PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; REG. NO/DATE: EU/1/18/1289 20180625
1713823 1490064-1 Sweden   See Pricing PRODUCT NAME: SIMEPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
0398460 12/2004 Austria   See Pricing PRODUCT NAME: DROSPIRENON IN KOMBINATION MIT ESTRADIOL; NAT. REGISTRATION NO/DATE: 1-25178, 1-25179 20031127; FIRST REGISTRATION: NL RVG 27505 20021211
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Mallinckrodt
McKesson
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.